Freedom Broker expressed concerns about the common viral platform shared between SRP-9004 and ELEVIDYS, noting it raises "systemic safety concerns" for Sarepta's gene therapy platform. The firm also highlighted financial challenges, warning that despite cost reductions, Sarepta risks violating covenants of its $600 million credit facility and "lacks a reliable source of funds" to repay over $1 billion in debt due in 2027. The dramatic price target reduction of nearly 87% reflects Freedom Broker's diminished outlook for the biotechnology company amid these mounting operational and financial challenges. In other recent news, Sarepta Therapeutics has temporarily halted all U.S. shipments of its drug Elevidys to address regulatory concerns. This decision is part of efforts to update the drug's label with a black box warning due to potential liver risks, including acute liver injury and failure.